Drug intelligence / Profile preview

RQ-3200

Development stage: Preclinical
Lead developer: RNAcure
Modality: mRNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Vaccines & Immunotherapeutics
Administration: Intramuscular

Overview

RQ-3200 is an mRNA-based vaccine candidate developed by RNAcure (Suzhou RNAcure Genetic Technology) for the prevention of respiratory syncytial virus (RSV) infection. The vaccine utilizes mRNA technology to deliver genetic instructions for an RSV-specific antigen, designed to stimulate the host's immune system to produce protective antibodies and T-cell responses. As of the latest pipeline data, RQ-3200 is in the early stages of development, leveraging RNAcure's proprietary mRNA synthesis and delivery platforms.

Targets

RSV F (Respiratory syncytial virus fusion protein)

Beyond the preview

Go deeper on RQ-3200.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on RQ-3200.

Explore the full profile